Global pharma company UCB has signed an agreement to acquire a new campus for its UK operations in Windlesham.
It has acquired the 19 hectare site in Windlesham from Eli Lilly and Company Limited and says the new facility will support more than 650 high-value jobs in scientific research, translational medicine, clinical development, early manufacturing and commercial roles.
The campus will become home to one of UCB’s three global Research and Development hubs, supporting cutting-edge research and development, early manufacturing and commercialisation of medicines aiming to transform the lives of people living with severe immunological and neurological conditions.
Business and Industry Minister Nadhim Zahawi said: “It’s fantastic to see that UCB has re-affirmed its commitment to the UK’s world-leading life sciences sector, and I welcome the role this facility will play in creating hundreds of high value jobs in the years to come.
“UCB’s investment demonstrates the huge opportunity for companies investing in UK science and research with government support, cementing the UK’s status as a global science superpower.”
Jean-Christophe Tellier, Chief Executive Officer at UCB said: “We have a strong track record of discovering medicines in the UK which go on to make a difference to the lives of patients worldwide.
“I am delighted to have signed an agreement to secure this new campus for our UK hub, from which our scientists will be able to continue to develop their extensive collaborations with some of the most innovative universities, bio-techs and medical research charities, bringing even greater benefit for patients.”
Collaborate with us to connect with organisations, people and ideas